Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: A pilot study

Bone Marrow Transplantation

Volumn 49, Issue 1, 2014, Pages 73-79

  Lum, L G ^a,b   Thakur, A ^a   Pray, C ^a   Kouttab, N ^c   Abedi, M ^d   Deol, A ^a   Colaiace, W M ^c   Rathore, R ^c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c ROGER WILLIAMS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Activated T cells; Autologous SCT; Bispecific antibody; Non Hodgkin's lymphoma

Indexed keywords

CARBOPLATIN; CD20 BISPECIFIC ANTIBODY; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IBUPROFEN; IFOSFAMIDE; INDIUM 111; INTERLEUKIN 2; MONOCLONAL ANTIBODY; PARACETAMOL; PETHIDINE; PREDNISOLONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW; CASE REPORT; CELL EXPANSION; CELL MIGRATION; CHILL; CYTOTOXICITY; FEVER; HEADACHE; HUMAN; HUMAN CELL; HYPOTENSION; LARGE CELL LYMPHOMA; LIVER; LOW DRUG DOSE; LUNG; MALAISE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; SAFETY; T LYMPHOCYTE; THERAPY DELAY;

AGED; ANTIBODIES, BISPECIFIC; ANTIGENS, CD20; ANTIGENS, CD3; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-2; LEUKAPHERESIS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PHENOTYPE; PILOT PROJECTS; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES;

EID: 84891888501     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.133     Document Type: Article

References (34)

1. Anderson DR, Grillo-Lopez A, Varns C, Chambers KS, Hanna N. Targeted anticancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans 1997; 25: 705-708.
2. Lambert JF, Rahore R, Lum LG, Oblon DJ, Malik SP, Colvin GA et al. Immune consolidation with rituximab following autologous stem cell transplantation for non-Hodgkin's lymphoma: An interim report of a pilot study with historical controls. In: Dicke KA, Keating A (eds) Stem Cell and Targeted Therapy Proceedings of the 11th INt'l Symposium. Carden Jennings: Charlottesville, NC, 2003, pp 149-161, .
3. Elfenbein GJ, Lum LG, Rathore R, Lambert JF, Falvey MT. Interim report of an historically controlled trial of rituximab after autologous stem cell transplanation for non-Hodgkin's lymphoma. Blood 2003; 102: 295b.
4. Horwitz SM, Negrin RS, Blume KG, Breslin S, Stuart MJ, Stockerl-Goldstein KE et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin's lymphoma. Blood 2004; 103: 777-783.
5. Kamezaki K, Kikushige Y, Numata A, Miyamoto T, Takase K, Henzan H et al. Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma. Bone Marrow Transplant 2007; 39: 523-527.
6. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-2195.
7. Johnson P, Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol 2003; 30: 3-8.
8. Manches O, Lui G, Chaperot L, Gressin R, Molens JP, Jacob MC et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003; 101: 949-954.
9. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22: 7359-7368.
10. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003; 171: 1581-1587.
11. Lum LG. Immunotherapy with activated T cells after high dose chemotherapy and PBSCT for breast cancer. In: Dicke KA, Keating A (eds). Carden Jennings: Charlottesville, NY, 2000, pp 95-105.
12. Gall JM, Davol PA, Grabert RC, Deaver M, Lum LG. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B-cells and bypass complement-mediated Rituximab-resistance in vitro. Exp Hematol 2005; 33: 452-459.
13. Van Wauwe JP, De Mey JR, Gooseens JG. OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. J Immunol 1980; 124: 2708-2713.
14. Weiss A, Imboden JB. Cell surface molecules and early events involved in human T lymphocyte activation. Adv Immunol 1987; 41: 1-38.
15. Anderson PM, Bach FH, Ochoa AC. Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Preliminary results in children with acute lymphocytic leukemia and neuroblastoma. Cancer Immunol Immunother 1988; 27: 82-88.
16. Ochoa AC, Hasz DE, Rezonzew R, Anderson PM, Bach FH. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets. Cancer Res 1989; 49: 963-968.
17. Sen M, Wankowski DM, Garlie NK, Siebenlist RE, Van Epps D, LeFever AV et al. Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu tumors. J Hematother Stem Cell Res 2001; 10: 247-260.
18. Uberti JP, Joshi I, Ueda M, Martilotti F, Sensenbrenner LL, Lum LG. Preclinical studies using immobilized OKT3 to activate human T cells for adoptive immunotherapy: optimal conditions for the proliferation and induction of non-MHC restricted cytotoxicity. Clin Immunol Immunopathol 1994; 70: 234-240.
19. Ueda M, Joshi ID, Dan M, Uberti JP, Chou T-H, Sensenbrenner LL et al. Preclinical studies for adoptive immunotherapy in bone marrow transplantation: II. Generation of anti-CD3 activated cytotoxic T cells from normal donors and autologous bone marrow transplant candidates. Transplantation 1993; 56: 351-356.
20. Grabert RC, Cousens LP, Smith JA, Olson S, Gall J, Young WB et al. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation. Clin Cancer Res 2006; 12: 569-576.
21. Coiffier B, Thieblemont C, Van Den NE, Lepeu G, Plantier I, Castaigne S et al. Longterm outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010; 116: 2040-2045.
22. Bosly A, Coiffier B, Gisselbrecht C, Tilly H, Auzanneau G, Andrien F et al. Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen. J Clin Oncol 1992; 10: 1615-1623.
23. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der LH, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
24. Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Acholonu S, Anderlini P et al. Concurrent administration of high-dose rituximab before and after autologous stemcell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 2005; 23: 2240-2247.
25. Ahmadi T, McQuade J, Porter D, Frey N, Loren AW, Goldstein SC et al. Potential prolongation of PFS in mantle cell lymphoma after R-HyperCVAD: auto-SCT consolidation or rituximab maintenance. Bone Marrow Transplant 2011; 47: 1082-1086.
26. Porter DL, Kalos M, Zheng Z, Levine B, June C. Chimeric antigen receptor therapy for B-cell malignancies. J Cancer 2011; 2: 331-332.
27. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3: 95ra73.
28. Lum LG, Thakur A, Rathore R, Al-Kadhimi Z, Uberti JP, Rathanatharathorn V. Phase I Clinical Trial Involving Infusions of Activated T Cells Armed with Anti-CD3 x Anti-Her2neu Bispecific Antibody in Women with Metastatic Breast Cancer: Clinical, Immune, and Trafficking Results.Oct. ASCO Breast Cancer Symposium 2010: Washington, DC 1-3, 2010.
29. Thakur A, Lum LG. Cancer therapy with bispecific antibodies: clinical experience. Curr Opin Mol Ther 2010; 12: 340-349.
30. Lum LG, Thakur A. Bispecific antibodies for arming activated T cells and other effector cells for tumor therapy. In: Kontermann RE (eds) Bispecific Antibodies. Springer-Verlag Berlin Heidelberg: Stuttgart, pp 243-271, 2011.
31. Lum LG, Thakur A, Liu Q, Deol A, Al-Kadhimi Z, Ayash L et al. CD20-Targeted T Cells after Stem Cell Transplantation for Non-Hodgkin Lymphoma. Biol Blood Marrow Transplant 2013; 19: 925-933.
32. Jin N-R, Lum LG, Ratanatharathorn V, Sensenbrenner LL. Anti-CD3-activated splenocytes enhance survial in lethally irradiated mice after transplant of syngeneic hematopoietic stem cells. Exp Hematol 1995; 23: 1331.
33. Hexner EO, net-Desnoyers GA, Zhang Y, Frank DM, Riley JL, Levine BL et al. Umbilical cord blood xenografts in immunodeficient mice reveal that T cells enhance hematopoietic engraftment beyond overcoming immune barriers by stimulating stem cell differentiation. Biol Blood Marrow Transplant 2007; 13: 1135-1144.
34. Lum LG, Thakur A, Liu Q, Deol A, Al-Kadhimi Z, Ayash L et al. CD20-targeted T cells after stem cell transplant for high risk and refractory non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2013; 9: 925-933.